Xtant Medical Holdings Inc (XTNT)
XASE:XTNT
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.28Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call describes clear operational and financial progress: return to profitability, materially improved adjusted EBITDA, stronger cash and a sharpened strategic focus on higher-margin, in-house biologics. Management highlighted meaningful product launches and a scaled sales organization to drive future organic growth. However, near-term headwinds are significant in reported (GAAP) top-line guidance due to the divestiture and expiration of nonrecurring license revenue, plus short-term declines in biologics and hardware, inventory charges and some increased compensation costs. On balance, the improvements in profitability, cash generation, margin expansion and strategic positioning outweigh the transitory revenue headwinds, though execution risk remains in ramping branded biologics sales and offsetting lost nonrecurring revenue.Company Guidance
Quarterly Revenue Growth
Q4 2025 revenue of $32.4M, up 3% versus Q4 2024 ($31.5M). Management noted the headline number was reduced by ~ $2M of revenue in the quarter due to the earlier-than-expected Coflex/Paradigm closing.
Full-Year Revenue and Growth
Full-year 2025 revenue of $133.9M, up 14% versus $117.3M in 2024 and toward the upper end of prior guidance ($131M–$135M).
Return to Profitability and Strong Adjusted EBITDA
Full-year 2025 net income of $5.0M (EPS $0.03) versus a $16.5M loss in 2024; full-year adjusted EBITDA $16.3M versus an adjusted EBITDA loss of ~$2.3M in 2024. Q4 adjusted EBITDA $1.9M versus ~$0.4M in Q4 2024; Q4 net income $57K versus a $3.2M loss prior-year.
Improved Gross Margin
Full-year 2025 gross margin improved to 62.9% from 58.2% in 2024 (approximately +470 bps), driven by favorable sales mix and scale despite offsetting inventory charges.
Stronger Cash and Balance Sheet
Cash, cash equivalents and restricted cash of $17.3M as of 12/31/2025 (up from $6.2M as of 12/31/2024). Management also received additional proceeds (~$10.7M) and satisfaction of an $8.2M promissory note related to the Companion Spine transaction after year-end, used to reduce borrowings.
Completed Strategic Divestiture
Sale of noncore Coflex interlaminar stabilization assets and international Paradigm Spine entities to Companion Spine closed in early December; final purchase price ~ $21.4M. Management says transaction sharpened focus on higher-margin biologics and improved capital position.
Product Portfolio Expansion and New Launches
Launched nanOss Strata (synthetic bone graft), CollagenX (bovine collagen particulate), plus continued rollouts of Trivium, OsteoVive Plus and OsteoFactor Pro. Management reported excellent early surgeon feedback and positioned offerings across all 5 major orthobiologic categories.
Commercial Investment and Sales Force Expansion
Company doubled the number of regional sales reps in 2025 and plans to add significant national accounts resources in 2026 to drive institutional adoption and accelerate biologics revenue.
Cost Discipline and Operating Expense Control
Total operating expenses decreased to $77.0M in 2025 from $80.3M in 2024. Sales & marketing expenses declined year-over-year (full-year $45.5M vs $49.2M) driven by lower commissions and reduced compensation expense related to headcount.
Guidance Emphasizes Self-Sufficiency
Management guided 2026 revenue to $95M–$99M and emphasized commitment to maintaining positive free cash flow and no anticipated need for external capital.
XTNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XTNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $0.54 | $0.56 | +2.76% |
Nov 10, 2025 | $0.76 | $0.76 | -0.66% |
Aug 12, 2025 | $0.59 | $0.67 | +14.14% |
May 12, 2025 | $0.52 | $0.60 | +14.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xtant Medical Holdings Inc (XTNT) report earnings?
Xtant Medical Holdings Inc (XTNT) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Xtant Medical Holdings Inc (XTNT) earnings time?
Xtant Medical Holdings Inc (XTNT) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XTNT EPS forecast?
Currently, no data Available